Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Traitements de palier 5 dans l’asthme
Journal ArticleDOI
Biothérapie dans l’asthme sévère : ce qu’il faut savoir
TL;DR: In this paper, the authors describe a procedure for identifying severe and severe asthme severe, etablir ses caracteristiques phenotypiques, choisir la biotherapie, se fixer des objectifs therapeutiques, evaluer la biotherapy and deciding les modalites de suivi et de prise en charge.
Journal ArticleDOI
Biothérapies dans l’asthme sévère de l’adulte: Biotherapies for severe asthma in adults
TL;DR: La diminution de dose ou le sevrage d’une corticotherapie orale au long cours obtenu chez certains patients est egalement un progres therapeutique important, ce qui permettra de completer l’arsenal therapeutiques dans l�’asthme T2 and ouvrira des perspectives nouvelles dansL’Asthme non allergique et non e
Journal ArticleDOI
Die blühende Zukunft der Immuntherapie bei Allergien
Ina Haasler,Christian Taube +1 more
TL;DR: Bei der Allergen-Immuntherapie (AIT) rührt sich was, es sind inzwischen neue Therapeutika verfügbar, etwa Antikörper, rekombinante Proteine oder Peptide, die nur 13 bis 17 Aminosäuren lang sind.
Journal ArticleDOI
Alergología en la práctica general
M. Raffard,H. Partouche +1 more
TL;DR: A continuación, puede practicar una inmunoterapia especifica siguiendo las reglas de la buena practica as discussed by the authors.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.